2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Biological activity
Description
Target:
5-HT Receptor
In Vivo
In Vitro
Kinase Assay
Cell Assay
Animal Administration
References
[1]. Sheehan DV, Locklear J, Sveds?ter H, Datto C. Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate. Int Clin Psychopharmacol. 2012 Sep;27(5):239-48.
[2]. Endicott J, Sveds?ter H, Locklear JC. Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder. Neuropsychiatr Dis Treat. 2012;8:301-311.
[3]. Lee JG, Lee JI, Kim YT, Kim CE, Kim CY, Yoon JS, Yoo SY, Kim YH. Safety of quetiapine fumarate extended release in the treatment of Korean patients with acute schizophrenia. Hum Psychopharmacol. 2012 Jul;27(4):403-10. doi: 10.1002/hup.2241.
[4]. Thase ME, Demyttenaere K, Earley WR, Gustafsson U, Udd M, Eriksson H. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression. Depress Anxiety. 2012 Jul;29(7):574-86. doi: 10.1002/da.21970.
[5]. Katila H, Mezhebovsky I, Mulroy A, Berggren L, Eriksson H, Earley W, Datto C. Randomized, Double-Blind Study of the Efficacy and Tolerability of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Elderly Patients With Major Depressive Di
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
